Previous Close | 231.77 |
Open | 234.15 |
Bid | 92.60 x 900 |
Ask | 259.99 x 1100 |
Day's Range | 226.28 - 236.11 |
52 Week Range | 217.20 - 460.21 |
Volume | |
Avg. Volume | 576,138 |
Market Cap | 11.74B |
Beta (5Y Monthly) | 1.23 |
PE Ratio (TTM) | 30.13 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Investors are optimistic about Charles River (CRL) due to the strong first-quarter results.
Charles River (CRL) broadens the scope of the products and services across the drug discovery and early-stage development continuum through focused acquisitions.
Charles River (CRL) Q1 results highlight 9.8% organic revenue growth, driven by strength across all three segments.